The Improving Access to Affordable Prescription Drugs Act
The summary of the act is provided by www.citizen.org. Information below is taken directly from the Section-by-Section summary provided by the organization.
The act is divided into 18 sections. We've highlighted the most important pieces of the legislation.
Title I - Transparency
Sec. 101 Drug manufacturer reporting
Sec. 102 Determining the public and private benefit of co-payment coupons and other patient assistance programs
Title II - Access and Affordability
Sec.201 Negotiating fair prices for Medicare prescription drugs
Sec.202 Prescription drug price spikes
Sec.203 Acceleration of the closing of the Medicare Part D coverage gap
Sec.204 Importing affordable and safe drugs
Sec.205 Requiring drug manufacturers to provide drug rebates fro drugs dispensed to low-income individuals
Sec.206 Cap on prescription drug cost-sharing
Title III - Innovation
Sec.301 Prize fund for new and more effective treatments of bacterial infections
Sec.302 Public funding for clinical trials
Sec.303 Rewarding innovative drug development
Sec.304 Improving program integrity
Title IV - Choice and Competition
Sec.401 Preserving access to affordable generics
Sec.402 180-Day exclusivity period amendments regarding first applicant status
Sec.403 180-Day exclusivity period amendments regarding agreements to defer commercial marketing
Sec.404 Increasing generic drug competition
Sec.405 Disallowance of deduction for advertising for prescription drugs
Sec.406 Product Hopping
Each week in October we will highlight a Title of the bill and share editorials and other information with you. Check back for more information.
Week of:
-
October 1: Title II - Access and Affordability
-
October 8: Title III - Innovation
-
October 15: Title IV - Choice and Competition
-
October 22: Title I - Transparency